28 Liberty Street, 39th Floor
About BeyondSpring Inc.
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and Phase 2/3 clinical program in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Stock Symbol: BYSI
Stock Exchange if applicable: NASDAQ
57 articles with BeyondSpring Inc.
BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources, effectively immediately.
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 1,851,852 ordinary shares at a public offering price of $13.50 per share
BeyondSpring Inc. announced the launch of an underwritten public offering of its ordinary shares.
BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia
BeyondSpring Inc. announced that the Company has enrolled its first patient in a Phase 3, Study 106, clinical trial with its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia Study 106 is enrolling patients receiving TAC chemotherapy plus Neulasta vs. TAC plus Plinabulin and Neulasta, to demonstrate Plinabulin’s exceptional ability to prevent CIN.
BeyondSpring’s Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors
BeyondSpring Inc. announced that the United States Patent Office has granted the Company a new patent, U.S. Patent No. 10,357,491 B2, for methods of treating a brain tumor by administering Plinabulin..
In a head-to-head study, BeyondSpring’s plinabulin stood up to Amgen’s Neulasta (pegfilgrastim) in a quality of life study to prevent neutropenia, a common side effect for chemotherapy patients.
Lan Huang, chief executive officer of BeyondSpring, believes her company has the “secret sauce” that could provide beneficial treatment to chemotherapy-induced neutropenia, a common side effect for chemotherapy patients.
BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia.
Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF
BeyondSpring Presented Latest Clinical Results at 2018 American Society of Hematology (ASH) Annual Meeting
BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Japan Patent Office (JPO) has granted the Company a new patent—JP Patent No. 6,411,523—for certain methods of preventing chemotherapy-induced neutropenia (CIN) with BeyondSpring’s lead asset, Plinabulin, a marine-derived small-molecule, in combination with taxane.
Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®
BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today reported new data from its clinical program for Plinabulin, which demonstrated a superior immune profile compared to Neulasta (pegfilgrastim) based on promyelocytes and immature neutrophil data from clinical study.
Study Opens of BeyondSpring’s Lead Asset, Plinabulin, and Nivolumab + Ipilimumab in Small-Cell Lung Cancer
Rutgers Trial Aims to Demonstrate Reduction in Immune-Related Adverse Events, While Adding to Anti-Cancer Immune Effects for Patients
BeyondSpring Inc. announced today that the Company will present clinical data on its lead asset, Plinabulin, at three upcoming scientific conferences:
More and more pharma companies follow the trend of planning initial public offerings on the Hong Kong Stock Exchange. Another trend following this path is the number of prominent investment bankers who have left their firms for biotech companies in the former British colony.
BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
BeyondSpring Inc. announced the presentation of preclinical data from the Company’s lead asset, Plinabulin, at the American Association for Cancer Research (AACR) Annual Meeting, being held on April 14-18, 2018, at McCormick Place in Chicago.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
BeyondSpring Summarizes Key Messages From KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia
The data was recently presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.
BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The Phase 2 portion of its global Phase 2/3 clinical trial demonstrated that the duration of severe neutropenia data for Plinabulin is very similar to the DSN of Neulasta.
BeyondSpring to Present Data From Phase II Portion of Study 105 Phase II/III Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Company to host conference call on Jan. 29 at 8:30 A.M. ET to review data.
BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent Member
Mr. Fabbio was also appointed to the Board's Audit Committee and will serve as Chair of that committee.